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Classical swine fever virus (CSFV) C-strain “Riems” escape variants generated under selective antibody pressure with
monoclonal antibodies and a peptide-specific antiserum in cell culture were investigated. Candidates with up to
three amino acid exchanges in the immunodominant and highly conserved linear TAV-epitope of the
E2-glycoprotein, and additional mutations in the envelope proteins ERNS and E1, were characterized both in vitro
and in vivo.
It was further demonstrated, that intramuscular immunization of weaner pigs with variants selected after a series of
passages elicited full protection against lethal CSFV challenge infection. These novel CSFV C-strain variants with
exchanges in the TAV-epitope present potential marker vaccine candidates. The DIVA (differentiating infected from
vaccinated animals) principle was tested for those variants using commercially available E2 antibody detection
ELISA. Moreover, direct virus differentiation is possible using a real-time RT-PCR system specific for the new C-strain
virus escape variants or using differential immunofluorescence staining.Introduction
Classical swine fever virus (CSFV) is one of the most im-
portant pathogens affecting domestic pigs and wild boar
[1]. CSFV, together with Border disease virus (BDV) and
Bovine viral diarrhea virus (BVDV), is grouped into the
genus Pestivirus of the Flaviviridae family [2]. Pesti-
viruses are small, enveloped, single plus-stranded RNA
viruses and their genome is approximately 12 300 nucleo-
tides long and flanked by 5’-terminal and 3’-terminal
non-translated regions (5’-NTR, 3’-NTR) [3]. Envelope
glycoprotein E2 is the main immunogen, essential for rep-
lication [4]. Moreover, it was shown that it plays a role in
viral adsorption to host cells together with other surface
proteins, namely ERNS and E1 [5,6]. The E2 protein forms
homo- and heterodimers with the E1 protein [7–9]. So far,
it is not known which regions in the E2 and E1 proteins
are responsible for dimerization. The N-terminus of glyco-
protein E2 displays different antigenic domains with both
linear and discontinuous epitopes [10,11]. An important
linear epitope located in the so-called “A domain” is* Correspondence: martin.beer@fli.bund.de
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reproduction in any medium, provided the orthe TAV-epitope consisting of the amino acids (aa)
TAVSPTTLR (aa 829 to 837 in the CSFV polyprotein).
This motif is highly conserved among CSFV strains but
divergent in BVDV and BDV strains [12]. Several mono-
clonal antibodies used in CSFV diagnosis and research as
well as polyclonal hyperimmune sera bind to this epitope
(e.g. WH303 (Veterinary Laboratories Agency, Weybridge
Surrey, UK) and A18 (IDEXX Laboratories, Shiphol-Rijk,
The Netherlands)). In addition, the TAV-epitope plays
a significant role in CSFV replication [13]. Especially,
CSF-specific diagnostic ELISA detect antibodies directed
against the conserved A-domain of the E2 structural
glycoprotein, where the TAV-epitope is located [14].
Knowledge about this antibody binding site is therefore
not only valuable to understand glycoprotein interactions,
cell tropism, virulence, and immunology but can also be
used as a target for marker vaccine and corresponding
discriminatory assay development [14–16]. An example
for these assays is the TAV-epitope based ELISA published
by Lin et al. [17]. However, all these approaches are exclu-
sively based on genetic engineering of marker vaccine can-
didates. At least in Europe, genetically modified
organisms, especially the ones that enter the food chain,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and this fact can lead to obstacles in both the licensing
process and utilization of the final product.
In the study presented, an alternative approach was
utilized that did not involve genetic engineering. In detail,
C-strain “Riems” vaccine virus served as template for
directed escape variant generation. This vaccine is known
to be highly effective and safe after oral and intramuscular
vaccination [18]. The concept was to force the vaccine
strain C-strain “Riems” into TAV-epitope escape variant
formation through selective antibody pressure. This pres-
sure was triggered by monoclonal antibodies and poly-
clonal rabbit sera against a synthetic TAV peptide. This
concept is well known for some other viruses e.g. [19,20]
but so far, it has not been used for CSFV. To ensure a
standardized approach and to optimize the use of possible
variants, mainly commercially available monoclonal anti-
bodies were employed. Resulting escape variants were
characterized both in vitro (sequence analyses, growth
characteristics, detectability with commercially available
antibodies, stability, and behavior in diagnostic tests), and
in vivo (safety and efficacy in challenge experiments after
intramuscular administration of the variants). Moreover,
concepts for genetic and serological DIVA were explored.
Materials and methods
Cell culture and virus propagation
Cells and viruses were grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% BVDV-
free fetal bovine serum at 37°C in a humidified atmos-
phere containing 5% CO2. EFN (embryonic piglet kidney
cells) and PK15 (porcine kidney) cells were obtained
from the Collection of Cell Lines in Veterinary Medicine
(CCLV), Friedrich-Loeffler-Institut (FLI), Insel Riems,
Germany.
For cell cultivation in roller tubes, EFN cells were cul-
tivated for one week at 37°C with DMEM containing 5%
foetal calf serum (FCS) until a final cell density of
2.5 × 105 cells/ mL. For virus propagation, 30 mL of a
24 h old cell suspension were incubated for one hour at
37°C with the virus isolate in the roller tube. After
addition of DMEM (containing 10% horse serum) to a
final volume of 300 mL, the cells were incubated for
three days at 37°C on roller drums.
Generation of polyclonal rabbit sera against CSFV E2
TAV-epitope
Two rabbits were intramuscularly vaccinated with 1 mL
synthetic CSFV E2 TAV peptide (prolonged variant) at a
concentration of 1 mg/mL (CTAVSPTTLRTEVVK-KLH
(keyhole limpet haemocyanin) coupled) (EMC, Tübingen,
Germany). To this means, 1 mg peptide was dis-
solved in 250 μL water and 750 μL PBS (phosphate
buffered saline). One-hundred microliters of PolygenTM(MVP Technologies, Omaha, NE, USA) were added as the
adjuvant. The animals were boostered with 1 mL peptide
solution five times at a four week interval. Serum samples
were taken monthly, always one week after booster
vaccination. Total serum was prepared from blood six
months after the first immunization. The rabbit sera were
tested in the CSFV specific E2 ELISA (HerdChek CSFV
Ab, IDEXX) and in virus neutralization tests with CSFV
strain Alfort/187 as described previously [9].
Selection of E2 escape variants from cell culture
supernatants
C-strain “Riems” vaccine virus batch SP 867/2 (4.5.2007)
was used as the primary material. To put it under selective
pressure, virus dilutions were incubated in cell culture
medium for 2–3 h at room temperature with different
mixtures of the E2 specific monoclonal antibodies,
namely A18I (IDEXX Laboratories, Shiphol-Rijk, The
Netherlands), A18B (Dr. Bommeli AG, Liebefeld,
Switzerland), A18C (Cedi-Diagnostics, Lelystad, The
Netherlands), HC34 (Community Reference Laboratory
for CSF, Hannover, Germany) or WH303 and WH211
(Veterinary Laboratories Agency Weybridge, United
Kingdom), respectively. As a standard protocol, 100 μL
virus suspension was incubated with 100 μL antibody
suspension containing 0.1 to 0.25 mg/mL of the respective
antibody. Since the outcome of these steps was unpredict-
able, different concentrations and mixtures were utilized
by way of trial. To impose additional selective pressure on
the target region of promising candidates, polyclonal
rabbit sera of CTAVSPTTLRTEVVK-peptide immunized
rabbits were used in the same manner (see above). After
infection of EFN cells with the virus antibody mixtures,
cells were grown for three days. Supernatants were col-
lected and cells were stained by immunofluorescence (IF)
staining using the pestivirus NS3 specific C16 antibody as
described elsewhere [21]. For isolation of single plaque
infected wells, supernatants of positive wells were titrated
on EFN cells. Subsequently, the supernatants were used
for further passaging under selective E2 antibody pressure.
The viruses obtained were in a first step sequenced in the
corresponding regions of the E1 and E2 protein. Viruses
with exchanges in the E2 TAV-epitope were used for fur-
ther passaging. Promising variants with sufficient growth
characteristics in cell culture were later on also sequenced
in the ERNS encoding region. In subsequent passages, anti-
body pressure was varied in terms of antibody concentra-
tion and antibody composition.
In summary, viruses were passaged several times
(repeatedly) using different antibody mixtures and con-
centrations for selection.
Promising candidates (named in alphabetical order of
their occurrence) were characterized and checked for
stability after 10 to 18 passages on EFN cells in cell
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this means, the obtained escape variants were partially
sequenced in the ERNS, E1, and E2 protein encoding
region (method see below). Moreover, differential im-
munofluorescence staining using E2 TAV-epitope specific
antibodies was carried out to monitor the behavior with
different routine monoclonal antibodies.
Monitoring of E2 escape variants
To monitor the behavior of the escape variants with rou-
tine monoclonal antibodies and thus test DIVA proper-
ties, cells infected with C-strain virus mutants were
stained 72 hours post infection (hpi) by immunofluores-
cence staining and analysed using a fluorescence micro-
scope (Olympus). Staining was carried out as described
previously [21]. The following antibodies were used: A18I
(IDEXX Laboratories, Shiphol-Rijk, The Netherlands),
A18C (Cedi-Diagnostics, Lelystad, The Netherlands),
HC34C, and C16 (provided by the Community Reference
Laboratory for CSF, Hannover, Germany). Virus titres
were obtained by end point titration of clarified EFN cell
supernatants as described elsewhere [22]. The titres
expressed as tissue culture infectious doses 50% (TCID50)
per mL were obtained after IF staining of the cell cultures
with monoclonal antibody C16 at 72 hpi.
RT-PCR for subsequent sequencing
Relevant virus escape variants were sequenced in the
ERNS, E1, and E2 regions using standard RT-PCR proto-
cols [23]. Total RNA of virus-infected cell culture super-
natants was extracted using the QIAampW viral RNA
mini kit (Quiagen, Hilden, Germany).
RT-PCR for sequencing was carried out with the Super
ScriptW III One-Step RT-PCR with PlatinumW Taq Kit
(Invitrogen GmbH, Karlsruhe, Germany) according to
the manufacturer´s instructions.
Reverse transcription was performed for 30 min at






E2-reverse (5´- TGTGTAGACCACTGGCTCG-3´). The
Beacon Designer 5.0 (Premier Biosoft International, Palo
Alto, USA) was used for primer selection. Oligonucleo-
tides were provided by Eurogentec (Eurogentec GmbH,
Cologne, Germany). DNA amplification was carried out
with a Mastercycler ep gradient S (Eppendorf AG, Ham-
burg, Germany) using 42 cycles of 15 s 94°C (DNA de-
naturation), 30 s 57°C (annealing), and 60 s 68°C
(elongation). DNA fragments were isolated from agarose
gels using the QIAEX IIW Gel Extraction Kit (Qiagen,
Hilden, Germany).Detection of C-strain “Riems” variants in cell culture
supernatant was performed using rRT-PCR protocol as
described previously [24] in an MX 3005 Pro cycler
(Stratagene, La Jolla, USA) and the newly developed
rRT-PCR system introduced here.
Sequencing was carried out using the BigDyeW
Terminator v1.1. Cyclo Sequencing Kit (Applied
Biosystems, Foster City, USA). Nucleotide sequence ana-
lysis was read with a 3130 Genetic Analyzer (Applied
Biosystems) and analyzed using the Genetics Computer
Group software version 11.0 (Accelrys Inc., San Diego,
CA, USA). All kits were used according to the manufac-
turer’s recommendations.Development of a rRT-PCR system specific for C-strain
“Riems” escape variants
For differentiation of escape variants from CSFV field
strains or C-strain “Riems” virus, a specific rRT-PCR system
was developed. Specific primers and a FAM labelled
TaqMan probe located in the TAV-epitope were designed.
The forward primer Q7-TAV-for 5´ ATA-GAG-TGC-
ACA-GTA-GTG-AGC-T −3` and reverse primer B5/2-
TAV-rev 5´- CTC-CTG-AAG-GTC-TTT-ATG-CAC-TC
−3` amplify a specific PCR product that is detected through
binding of the probe C-strain-TAV-LNA-FAM 5´-AAC
GAC TCT GAG AAC AG-3´. The probe contains seven
locked nucleic acids (LNA, presented in bold italic letters)
to enable the essential melting temperature. The AgPath-
IDTM One-Step RT-PCR Kit (Applied Biosystems, Warring-
ton, Cheshire, UK) was used in this protocol. The reverse
transcription was performed for 10 min at 45°C followed by
10 min enzyme inactivation and polymerase activation by
95°C. The PCR was performed in 42 cycles of each 15 s
95°C (denaturation), 20 s 60°C (annealing with end-point
fluorescence data collection) and 30 s 72°C (elongation).Challenge experiments
Three groups of five 8 to 12 week old pigs were intramus-
cularly immunized with escape variants Q7, S10, or O11
respectively. As control, a C-strain “Riems” vaccinated
group was included and treated likewise. Pigs of the first
three groups were intramuscularly immunized using 2 mL
cell culture supernatant containing 1× 105 TCID50/mL
(Q7), 1 × 105,25 TCID50/mL (S10), and 1× 10
5,25 TCID50/
mL (O11) virus, respectively. The C-strain “Riems” control
group was vaccinated with one vaccine dose of 1 mL (con-
taining 1 × 103.5 TCID50/mL) as recommended by the
manufacturer (RIEMSER Arzneimittel AG, Greifswald-
Insel Riems, Germany). All pigs were handled taking into
account all appropriate animal welfare regulations. The
experiments were approved by the internal animal welfare
officer at the FLI and the competent authority at regional
level and its independent animal protection and welfare
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LALLF M-V/TSD/7221.3-1.2-061/09.
Body temperature was measured daily and animals
were monitored for clinical symptoms throughout the
experiment. Serum samples were taken weekly for de-
termination of antibody response in the IDEXX CSFV
Ab ELISA (IDEXX Laboratories, Shiphol-Rijk, The
Netherlands) and Ceditest CSFV E2 ELISA (Cedi-
Diagnostics, Lelystad, The Netherlands). In addition,
sera were tested in neutralization assays against CSFV
strains “Roesrath” and “Alfort/187”. Analysis was per-
formed as described previously [25]. For analysis of T-
lymphocyte populations, whole blood samples were taken
on day 21 post immunization from three animals per
group. Lymphocytes were purified by Ficoll gradient cen-
trifugation using LSM 1077 (PAA). To investigate
antigen-specific T cell proliferation, lymphocytes were
in vitro cultivated in the presence of UV-inactivated CSFV
(C-strain, 0.1 MOI) for 5 days. Cells were stained directly
ex vivo or after antigenic re-stimulation using specific
mAb (AbD serotec), and FITC or PE labeled goat-anti-
mouse IgG isotype secondary antibodies (dianova) in PBS
containing 2% FCS, 1 mM EDTA and 0.1% NaN3. The fol-
lowing mAb were used: mouse-anti-pig CD4 (clone MIL-
17), mouse-anti-pig CD8 (clone MIL-12). Labeled cells
were quantitatively analyzed in a FACSCalibur flow
cytometer using CELLquest software (BD Biosciences).
Proliferation-specificity was calculated as stimulation
index (% antigen treated / % untreated control cells).
Four weeks after vaccination, challenge infection using
the highly virulent CSFV “Koslov” strain was carried out
by oronasal application of 2 mL whole blood virus suspen-
sion containing 1× 106,5 TCID50/mL challenge virus.
Three, 5, 7, and 10 days post infection, and weekly there-
after, blood and serum samples were taken. At days 3, 5, 7,
and 10 post challenge infection nasal swabs were taken.
Optimization of the DIVA concept
Besides the use of commercially available antibody ELISA
that are based on E2 according to the manufacturer’s
instructions, the ELISA plate was incubated for one hour
at room temperature with serum of CP7_E1E2_alf_TLA
[25] vaccinated pigs. The CP7_E1E2_alf_TLA vaccinated
pigs do not have TAV-epitope specific antibodies since the
TAV-epitope is exchanged. Afterwards the plates were
washed and used following the ELISA working instruc-
tions given by the manufacturer.
Results
Selection of E2 escape variants from cell culture
supernatants
After multiple passaging of C-strain “Riems”, virus var-
iants with differences in the glycoprotein E2 encoding
region were isolated from supernatants of embryonalpiglet kidney cells (EFN). A first generation of E2 escape
variants displayed a single nucleotide exchange in the
TAV-epitope of the E2 at nucleotide position 2870, asso-
ciated with a compensatory nucleotide exchange at pos-
ition 2122 in the E1 encoding region. Further incubation
of this variant with E2-specific neutralizing antibodies
and polyclonal serum derived from TAV-peptide immu-
nized rabbits led to the isolation of a new variant with
an additional exchange in the extended TAV-epitope at
nucleotide position 2889. Moreover, a third generation
of E2 variants featured an additional nucleotide ex-
change in the TAV-epitope of the E2 protein at position
2862. In detail, the TAV-epitope of wild-type C-strain-
consisted of amino acid sequence CTAVSPTTLR-
TEVVK. Variant B5/2 showed two exchanges resulting
in sequence CTAVSSTTLRTGVVK, and variant S10
showed sequence CTVVSSTTLRTGVVK. At this point,
a second compensatory exchange in the E1 protein at
nucleotide position 2099 was observed. All E2 escape
variants displayed an additional exchange at position
1649 in the ERNS protein. All these nucleotide exchanges
caused amino acid exchanges in the corresponding pro-
tein. An overview of the E2 escape variants is shown in
Table 1. Immunofluorescence staining of the E2 escape
variant S10 with the antibodies A18C (TAV-epitope-
specific; Cedi-Diagnostics), A18I (TAV-epitope-specific;
IDEXX Laboratories) and C16 (specific for nonstructural
protein 3; CRL) is shown in Figure 1. Whereas E2-
specific staining of the escape variant was negative even
after the 10th cell culture passage without antibody pres-
sure, the parental C-strain “Riems” virus was stained
positive with all E2 specific antibodies.
Stability of E2 mutants
To test the stability of the acquired exchanges in the TAV-
epitope, E2 escape variants were multiply passaged without
antibody pressure using EFN cells. The exchange in the E2
escape variant D9 at nucleotide position 2870 was stable
over more than ten cell culture passages. Escape variant
B5/2 with exchanges at nucleotide position 2870 and 2889
in the E2 protein and at position 2122 in the E1 protein
proved instable since the exchange at position 2889 was lost
after ten cell culture passages. The escape variants Q7, S10,
and O11 with nucleotide exchanges 2862, 2870, and 2889
in the TAV-epitope of the E2 protein as well as 2099 and
2122 in the E1 protein were stable over ten cell culture pas-
sages. The 14th passage of S10 was week positive with the
A18I antibody, single cells where stained positive (Table 2).
Similarly, the 16th passage of O11 was weak positive in the
immunofluorescence staining with antibodies A18B and
WH303. However, sequencing results of later passages of
Q7 (14th), S10 (18th), and O11 (17th) showed no evidence
for reversion of the new exchanges in the TAV-epitope and
the exchanges in the E1 protein, respectively (Table 1).
Table 1 Stability analysis of the E2 TAV escape variants D9, B5/2, Q7, S10, and O11 using partial sequencing of viral
proteins E1, E2, and ERNS (numbers indicate nucleotide positions differing from the parental C-strain “Riems”)




















ERNS 1649 1649 1649 1649 1649 1649 1649 1649 Isoleucin to Valine
E1 - - 2099 2099 2099 2099 2099 2099 Tyrosine to Histidine
2122 2122 2122 2122 2122 2122 2122 Aspartic acid to
Glutamic acid
E2 - - 2862 2862 2862 2862 2862 2862 Alanine to Valine
2870 2870 2870 2870 2870 2870 2870 2870 Proline to Serine
- 2889 2889 2889 2889 2889 2889 2889 Glutamic acid to Glycine
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escape variants Q7, S10, and O11
Different passages of the escape variants were tested
with the specific real-time RT-PCR (rRT-PCR) system.
Viruses of all passages were reliably detected with simi-
lar Cq-values (quantification cycle value) compared to
the universal CSFV specific system developed by Hoff-
mann et al. [26] (Table 3). To test the specificity of this
system, the EPIZONE reference RNA panel [24] com-
promising the RNA of 31 different Pestivirus strains was
tested and all samples scored negative. To further evalu-
ate the selectivity of the assay, the parental C-strain
“Riems” and CSFV strain “Koslov”, both belonging to the
genotype 1.1, were tested using highly positive samples
with Cq-values of about 15 in the CSF specific assay.




Figure 1 Staining of escape variant S10 with different monoclonal an
10th passage of E2 escape variant S10 with the monoclonal antibodies C16
positive virus control. As conjugate the alexa FluorW488 goat anti-mouse Igvariant-specific rRT-PCR with Cq-values that were 20 re-
spectively 18 Cq-values higher than in the CSF-specific
rRT-PCR. Subsequent testing of 20 additional non-CSFV
Pestivirus strains showed no false positive results.
Animal experiment with escape variants Q7, S10, and O11
Intramuscularly immunized pigs of all groups showed full
protection in challenge experiments with the highly viru-
lent CSFV “Koslov” strain four weeks after vaccination.
No CSF specific symptoms were observed. In each of the
Q7, S10, or O11 vaccinated groups one animal had mod-
erate fever for 2–4 days. The virus isolation of nasal swabs
remained negative throughout the experiment in all vacci-
nated animals. Real-time RT-PCR results of the nasal
swabs showed sporadic weak positive results in all vacci-




tibodies. Immunofluorescence staining of EFN cells infected with the
, A18C, and A18I, the parental C-strain “Riems” virus was used as
G secondary antibody was used (Invitrogen, Carlsbad, CA, USA).
Table 2 Stability analysis of the E2 TAV escape variants Q7, S10, and O11 using immunofluorescence staining with




















A18I - - - (SC) (SC) - - - +++
(Idexx)
A18B - - - - - - - (SC) +++
(Bommeli)
WH 303 - - - - - - - (SC) +++
C16 +++ +++ +++ +++ +++ +++ +++ +++ +++
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samples also showed weak positive results in the Q7, S10,
and O11 vaccinated group three days post challenge infec-
tion. Animals of the unvaccinated control group showed
highly positive results in the rRT-PCR of nasal swabs and
serum samples from three days after challenge infection
onwards and were positive in virus isolation of nasal
swabs.
In the neutralization test (NT) against CSFV strain “Roes-
rath”, all groups became positive three weeks afterTable 3 Results of different C-strain escape variants and
samples from the EPIZONE reference RNA panel in the
TAV escape variants specific rRT-PCR system compared
with the CSF specific rRT-PCR system published by
Hoffmann et al., 2005 [26]




C_strain No Cq. 28.3
Eystrup91 No Cq. 27.7
Alfort187 No Cq. 27.3
Koslov1128 No Cq. 27.2
Brescia No Cq. 30.5
Schweiz II No Cq. 28.4
Pader No Cq. 27.2
Bergen No Cq. 28
D4886/82/Ro No Cq. 28.1
Uelzen No Cq. 28.8
Spante No Cq. 27.8
Congenital Tremor No Cq. 30.4
Q7 10th passage 22.4 21.2
Q7 14th passage 21.9 20.4
S10 10th passage 21.4 20.5
S10 14th passage 20.9 19,2
S10 17th passage 21 20.1
O11 9th passage 20.9 20.1
O11 14th passage 20.2 19.5
O11 16th passage 21.6 20.1vaccination. One animal of the S10 vaccinated group stayed
negative until three days post challenge infection, but ten
days post challenge infection all vaccinated animals showed
neutralizing titers against CSFV strain “Roesrath” higher
than 6400 neutralizing doses 50% (ND50) (Figure 2a). In the
NT against CSFV strain “Alfort/187”, all vaccinated animals
displayed neutralizing antibodies three weeks after vaccin-
ation, and ten days post infection NT titers ranging from
2400 to>6400 ND50 (Figure 2b).
In the E2 specific ELISA (IDEXX Laboratories, Shiphol-
Rijk, The Netherlands) all groups vaccinated with escape
variants stayed negative or showed questionable results
until the day of challenge (four weeks after vaccination)
whereas C-strain “Riems” vaccinated animals were clearly
positive already three weeks after immunization (Figure 3a).
Pre-incubation of the E2 ELISA plates with CP7_E1E2_alf_-
TLA [25] vaccinated pig sera also showed negative results,
with about 30-37% average inhibition in all escape variant
vaccinated groups. C-strain “Riems” vaccinated pigs were
clearly positive four weeks after vaccination with about 60%
inhibition (Figure 3b). One week after challenge infection
all vaccinated pigs became positive. In the unvaccinated
control group, neutralizing antibodies were not detected in
the E2 ELISA nor in the NT.
To investigate alternative T-cell immunity after
immunization with escape variants, peripheral blood lym-
phocytes were monitored three weeks after immunization
and after in vitro antigen re-stimulation. Compared to un-
treated animals or animals vaccinated with the common C-
strain, all pigs vaccinated with escape variants showed high
amounts (up to 60% PBL maximum) of CD4+CD8+ T
cells in blood directly ex vivo (Additional file 1: Figure S1a)
as well as proliferation of those cells after antigenic re-
stimulation with UV-inactivated CSFV in vitro. In contrast,
proliferation of CD4+/CD8- T helper cells was detected
after re-stimulation of lymphocytes from pigs immunized
with classical C-strain “Riems” vaccine (Additional file 1:
Figure S1b).
In summary, pigs vaccinated with the different escape
variants showed protection in challenge experiments
comparable to C-strain “Riems” vaccinated pigs. The NT
Figure 2 a/b: Results of virus neutralization tests. Virus neutralization test against CSFV strains “Roesrath” (2a) and “Alfort/187” (2b). The
neutralization titers are given in a logarithmical scale.dpv: days post vaccination, dpi: days post challenge infection.
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Clear differences could be observed in the E2 ELISA.
Here, the C-strain “Riems” vaccinated pigs were positive
whereas pigs vaccinated with the escape variants stayed
negative or displayed questionable results. The pre-
incubation of the ELISA plates with CP7_E1E2_alf_TLA
vaccinated sera increased the specificity of the ELISA
system slightly but did not influence the sensitivity re-
markably. Pigs vaccinated with escape variants devel-
oped an alternative T cell immunity.
Discussion
The structural protein E2 is not only the main immuno-
gen of CSFV and therefore used in various vaccine con-
cepts, it also plays a major role in virulence, viral
adsorption to host cells and thus cell tropism, and virus
replication [5,6]. Knowledge about the antibody binding
sites, especially the TAVSPTTLR (aa 829 to 837) motif(TAV-epitope) in the antigenic A domain [12] can help
to generate promising marker vaccine concepts and
DIVA diagnostic approaches. To study the above men-
tioned mechanisms and to generate potential marker
vaccines, genetic engineering is most often employed
[14,27]. One example is the C-strain deletion mutant
described by Kortekaas et al. [15]. An alternative ap-
proach involves the isolation of escape variants occur-
ring under selective antibody pressure. While the former
is much more predictable in terms of deletion sites and
yields well characterized viruses by definition, the latter
has the advantage of more or less naturally occurring
mutations without genetic engineering. Since the escape
variants develop over several passages in cell culture, it
can be assumed that stability is optimized in this system,
e.g. through additional compensatory or adaptive muta-
tions. Especially the use of a well defined parental strain, i.
e. a vaccine strain that was used in millions of domestic
Figure 3 a/b: ELISA results. 3a) E2 specific ELISA (IDEXX) of Q7, S10, O11, or C-strain “Riems” positive control immunized pigs and a mock
control of unvaccinated pigs. 3b) E2 specific ELISA (Idexx) after saturation of antigen coated plate by incubation with serum of pigs vaccinated
with chimeric pestivirus CP7_E1E2alf_TLA containing E2 protein with modified TAV-epitop. dpv: days post vaccination, dpi: days post challenge
infection.
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cines will be administered to animals that enter the food
chain, reservations of politicians and consumers regarding
genetically modified organisms (GMO) have to be taken
into account. At least in several European countries, a vac-
cine that is not based on a GMO would facilitate the use
in case of a CSF outbreak. Furthermore, it is an advantage
if one generates escape variants through the use of anti-
bodies that are applied in commercial diagnostic test sys-
tems. This makes it more likely that animals vaccinated
with these escape variants display different antibody pat-
terns and thereby are no longer detectable with these
diagnostic test systems that are fully validated and already
tested for high throughput surveillance.
As a result of this study, different escape variants
could be isolated from cell culture supernatants after
various passages with antibody pressure. The antibodypressure was first realized in a less standardized ap-
proach with antibody mixtures by way of trial. Both, the
decision on the use of a certain mixture as well as the
outcome were highly incidental. In a second more tar-
geted and interlinked approach, TAV-epitope specific
polyclonal rabbit sera were used to intensify and direct
the pressure. Subsequently, these escape variants were
characterized both in vitro and in vivo.
Sequencing of stable variants revealed up to three
exchanges in the linear TAV-epitope. These exchanges
were accompanied by interesting, probably compensa-
tory exchanges especially in the E1 and the ERNS protein
encoding regions. These results suggest that the TAV-
epitope is probably involved in the heterodimer complex
formation with the E1 protein. Similar observations were
already made by Kortekaas et al. in 2010 [14], who
showed that genetically modified viruses with mutations
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compensatory mutations occurred.
In our study, adaptive exchanges were found in the E1,
ERNS, and E2 protein, dependent on the exchanges intro-
duced in the TAV-epitope. Interactions of glycoproteins
could be one major reason for the TAV-epitope being so
conserved among CSFV field strains. Of all available
CSFV strains, only the GPE- vaccine strain has a slightly
modified TAV-epitope with the amino acid sequence
TTVSPTTLR. Like the escape variants and many CSFV
field strains, GPE- possesses a glutamic acid in the E1 pro-
tein at amino acid position 583, but a tyrosine at amino
acid position 575 as all other known CSFV isolates.
Most escape variants proved to be stable even after
multiple passaging steps without pressure, but finally
some samples showed single cell staining in immuno-
fluorescence suggesting reversion. At least, no reversions
were seen after sequencing. Whether this is due to re-
version of the newly required exchanges in the TAV-
epitope or is caused by unspecific binding of the E2
TAV-specific antibody, for instance because of high anti-
body concentration, is still unclear. One explanation
could be the reversion of a minor quasispecies that
would not be reliably seen in sequence analyses. Another
possibility is that the isolated variant did not really start
from a single plaque but from a mixture that contained
the parental virus in small quantities. Given that the par-
ental variant could have a small fitness advantage, this
contamination could increase over time eventually leading
to a stainable amount. Regarding stability of potential vac-
cine candidates, it has to be kept in mind, that industry
scale vaccine production under good manufacturing prac-
tice (GMP) conditions can only use five passages of a seed
virus according to the European Pharmacopoeia. Thus,
stability over 10 passages is sufficient even when some
properties could be lost thereafter.
An interesting question is whether repeated experiments
would have led to the same escape variants. On the one
hand, mutations are random effects that cannot be pre-
dicted at least in time, but on the other hand, the specific
and adaptive mutations observed here seem to provide the
ability to survive antibody pressure. It was observed that
variants with the first exchange in the TAV epitope (nucleo-
tide 2870) as well as with one compensatory exchange
in the E1 (nucleotide 2122) occurred in independently
repeated experiments. A hypothesis for this uniform behav-
ior could be that these variants were already present in a
very small quasispecies. The other mutations occurred only
after several passages with different antibody compositions
and concentrations. Thus, an already existing quasispecies
is unlikely in this case. The use of the polyclonal anti-
peptide sera was apparently necessary to obtain variants
with more than two stable mutations, and the multistep ap-
proach seems to present a key factor for stable variants.However, since repetitions and experiments in parallel
were not conducted in general, these issues remain
speculative.
Late generations of escape variants that showed three
mutations in the TAV-epitope were tested in an animal
trial in comparison with the parental C-strain “Riems”
vaccine. Escape variants Q7, S10, and O11 elicited full
protection against challenge infection with the highly
virulent CSFV “Koslov” strain following intramuscular
vaccination. Pigs vaccinated with these variants showed
an enhanced T cell response that could be explained by
the experimental selection pressure on E2 specific Th2
immune response. The memory T cells taken three
weeks after immunization are able to expand after sec-
ond antigen contact in vitro. Therefore it can be antici-
pated that after challenge in vivo these antigen-specific
cells are able to proliferate as well and eliminate virus
infected cells. In addition, it can be assumed that after
challenge in vivo, antigen presentation and the following
T cell activation is more effective: After re-stimulation
with UV-inactivated whole virus in vitro, extracellular
antigen can only be presented via cross-presentation.
After challenge with living virus, antigen can be pre-
sented additionally by infected cells directly via MHC
class I.
The above mentioned fever reaction was the only clin-
ical sign and not accompanied by detectable amounts of
live virus in blood, serum or nasal swabs of these pigs.
Thus, protection was comparable to the one induced by
the parental C-strain “Riems”. This was underlined by
the very similar neutralizing antibody responses. Further
animal experiments are already under execution in order
to find out more about the onset of immunity, the mini-
mum protective dosage, virus transmission, and protec-
tion after oral immunization.
Efficacy and safety of a new vaccine are of great im-
portance, but for a possible marker vaccine, reliable and
stable DIVA properties are equally pivotal. The above
mentioned approach aims at using commercially avail-
able tools to differentiate infected from vaccinated pigs.
The underlying assumption is that escape variants bear-
ing modifications in the highly conserved CSFV specific
linear TAV-epitope would elicit neutralizing E2-specific
antibodies not recognized by the traditional E2-ELISA.
First passages were not fit for purpose in this regard
since animals vaccinated with these variants were posi-
tive in the commercial E2-ELISA (data not shown).
Similar observations were made by Kortekaas et al. for
the genetically engineered TAV mutants [15]. The con-
cept worked in principle with later generations but still
needs improvement. Pigs vaccinated with early passages
of Q7, S10, or O11 stayed negative or became only ques-
tionable in the E2 specific ELISA. In the end, this would
possibly work on the herd level in outbreak scenarios
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DIVA diagnostics using the E2-ELISA was to pre-
incubate the ELISA plates with sera of pigs immunized
with the chimeric pestivirus CP7_E1E2_alf_TLA. These
sera do not possess TAV-epitope specific antibodies but
all other E2 specific antibodies, so incubation of the
ELISA antigen should ensure that only TAV-epitope spe-
cific antibodies presented in the tested sera could bind.
An improvement was seen, but there is still room for
optimization. To further improve the DIVA principle,
development of a TAV-epitope specific peptide ELISA as
described by Holinka et al. in 2009 [28], Lin et al. in
2010 [17], and Kortekaas et al. in 2010 [14] would be
helpful. Another possibility is the use of a double check
approach where each tested sample is used in two differ-
ent coated ELISA wells, one presenting the E2 antigen
from the wild type CSFV and one presenting the E2
antigen from the TAV-escape variant. Thus, by analyzing
both results, a clear allocation of the tested samples to
wild type or TAV-escape variants should be possible.
Besides serological DIVA, direct discrimination from field
viruses is possible using the rRT-PCR system introduced
here. There is a certain lack of selectivity towards other
genotype 1.1 strains. This problem only occurs with sam-
ples that contain high amounts of virus that would be ac-
companied by clinical signs if occurring with genotype 1.1
field strains. For the parental C-strain “Riems” virus, these
amounts are never reached in the pig, and the vaccines
would not be applied in parallel. Moreover, recent field
strains detected in the European Union belong to genotype
2. Thus, problems in diagnostics arising from this minor
lack of selectivity are unlikely and could, in the worst case,
be solved by partial sequencing.
In summary, the escape variants obtained through select-
ive antibody pressure could be promising marker vaccine
candidates that would have the advantage that no genetic
engineering was used in the design. The accompanying
DIVA options have passed the proof of principle stage but
still have room for optimization. Furthermore, this study
might help to identify possible interacting domains of CSFV
glycoproteins in the hetero dimer complex formation. The
strategy to induce natural escape variants could be used in
future projects to learn more about the interactions by ana-
lyzing the resulting compensatory changes.Additional file
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vaccinated and unvaccinated animals, pigs immunized with escape
variants show high amounts of CD4/CD8 double positive T lymphocytes
directly ex vivo (A). Proliferation of double positive T cells is detectable
after antigenic re-stimulation with inactivated CSFV (B). Specificity was
calculated as the stimulation index (% antigen treated cells / % untreated
control cells).Competing interests
Riemser Arzneimittel AG financed the research leading to this article and is
currently applying for a patent relating to the contents of the manuscript.
No other competing interests exist.
Authors' contributions
IL carried out the cell culture based techniques leading to the escape
variants, investigated all samples from the related animal trials, performed
sequence analyses of escape variants and their passages, developed and
validated the specific real-time RT-PCR, and drafted the manuscript. SB
carried out the animal trials, participated in the conception and design of
the presented study, and critically revised the manuscript. UB analysed T-
lymphocyte populations ex vivo and after antigenic re-stimulation. PK carried
out the initial steps of escape variant formation in cell culture. HK and BL
produced and characterized the escape variants on roller drums and
adjusted the viruses to near industry scale production. MB conceived the
study, and participated in its design and coordination and helped to critically
revise the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Ulrike Kleinert, Doreen Reichelt, Claudia
Dettmer, Stefanie Knöfel, and Kersten Biebl for excellent technical assistance
throughout the project.
Author details
1Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Südufer 10, 17493,
Greifswald-Insel Riems, Germany. 2Institute of Immunology,
Friedrich-Loeffler-Institut, Südufer 10, 17493, Greifswald- Insel Riems,
Germany. 3Riemser Arzneimittel AG, An der Wiek 7, 17493, Greifswald-Insel
Riems, Germany. 4Institute of Virology and Immunoprophylaxis (IVI),
Sensemattstrasse 293, 3147, Mittelhaeusern, Switzerland.
Received: 2 September 2011 Accepted: 23 February 2012
Published: 20 April 2012
References
1. Edwards S, Fukusho A, Lefevre PC, Lipowski A, Pejsak Z, Roehe P,
Westergaard J: Classical swine fever: the global situation. Vet Microbiol
2000, 73:103–119.
2. Fauquet CM, Fargette D: International Committee on Taxonomy of
Viruses and the 3,142 unassigned species. Virol J 2005, 2:64.
3. Meyers G, Thiel HJ: Molecular characterization of pestiviruses. Adv Virus
Res 1996, 47:53–118.
4. van Gennip HG, Bouma A, van Rijn PA, Widjojoatmodjo MN, Moormann RJ:
Experimental non-transmissible marker vaccines for classical swine fever
(CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine 2002,
20:1544–1556.
5. Hulst MM, Moormann RJ: Inhibition of pestivirus infection in cell culture
by envelope proteins E(rns) and E2 of classical swine fever virus: E(rns)
and E2 interact with different receptors. J Gen Virol 1997, 78:2779–2787.
6. Wang Z, Nie Y, Wang P, Ding M, Deng H: Characterization of classical
swine fever virus entry by using pseudotyped viruses: E1 and E2 are
sufficient to mediate viral entry. Virology 2004, 330:332–341.
7. Rümenapf T, Unger G, Strauss JH, Thiel HJ: Processing of the envelope
glycoproteins of pestiviruses. J Virol 1993, 67:3288–3294.
8. Weiland E, Stark R, Haas B, Rümenapf T, Meyers G, Thiel HJ: Pestivirus
glycoprotein which induces neutralizing antibodies forms part of a
disulfide-linked heterodimer. J Virol 1990, 64:3563–3569.
9. Weiland E, Ahl R, Stark R, Weiland F, Thiel HJ: A second envelope
glycoprotein mediates neutralization of a pestivirus, hog cholera virus.
J Virol 1992, 66:3677–3682.
10. van Rijn PA, van Gennip HG, de Meijer EJ, Moormann RJ: Epitope mapping
of envelope glycoprotein E1 of hog cholera virus strain Brescia. J Gen
Virol 1993, 74:2053–2060.
11. Wensvoort G, Terpstra C, de Kluyver EP: Characterization of porcine and
some ruminant pestiviruses by cross-neutralization. Vet Microbiol 1989,
20:291–306.
12. Lin M, Lin F, Mallory M, Clavijo A: Deletions of structural glycoprotein E2
of classical swine fever virus strain alfort/187 resolve a linear epitope of
monoclonal antibody WH303 and the minimal N-terminal domain
Leifer et al. Veterinary Research 2012, 43:33 Page 11 of 11
http://www.veterinaryresearch.org/content/43/1/33essential for binding immunoglobulin G antibodies of a pig
hyperimmune serum. J Virol 2000, 74:11619–11625.
13. Risatti GR, Holinka LG, Carrillo C, Kutish GF, Lu Z, Tulman ER, Sainz IF, Borca
MV: Identification of a novel virulence determinant within the E2
structural glycoprotein of classical swine fever virus. Virology 2006,
355:94–101.
14. Kortekaas J, Vloet RP, Weerdmeester K, Ketelaar J, van Eijk M, Loeffen WL:
Rational design of a classical swine fever C-strain vaccine virus that
enables the differentiation between infected and vaccinated animals.
J Virol Methods 2010, 163:175–185.
15. Kortekaas J, Ketelaar J, Vloet RP, Loeffen WL: Protective efficacy of a
Classical swine fever virus C-strain deletion mutant and ability to
differentiate infected from vaccinated animals. Vet Microbiol 2011,
147:11–18.
16. Qi Y, Zhang BQ, Shen Z, Chen YH: Antigens containing TAVSPTTLR
tandem repeats could be used in assaying antibodies to Classical swine
fever virus. Acta Virol 2009, 53:241–246.
17. Lin GZ, Zheng FY, Zhou JZ, Cao XA, Gong XW, Wang GH, Qiu CQ: An
indirect ELISA of classical swine fever virus based on quadruple
antigenic epitope peptide expressed in E.coli. Virol Sin 2010, 25:71–76.
18. van Oirschot JT: Vaccinology of classical swine fever: from lab to field.
Vet Microbiol 2003, 96:367–384.
19. DeMaula CD, Bonneau KR, MacLachlan NJ: Changes in the outer capsid
proteins of bluetongue virus serotype ten that abrogate neutralization
by monoclonal antibodies. Virus Res 2000, 67:59–66.
20. Grummer B, Fischer S, Depner K, Riebe R, Blome S, Greiser-Wilke I:
Replication of classical swine fever virus strains and isolates in different
porcine cell lines. Dtsch Tierarztl Wochenschr 2006, 113:138–142.
21. Beer M, Wolf G, Pichler J, Wolfmeyer A, Kaaden OR: Cytotoxic T-lymphocyte
responses in cattle infected with bovine viral diarrhea virus. Vet Microbiol
1997, 58:9–22.
22. Leifer I, Hoffmann B, Hoper D, Bruun Rasmussen T, Blome S, Strebelow G,
Höreth-Böntgen D, Staubach C, Beer M: Molecular epidemiology of
current classical swine fever virus isolates of wild boar in Germany.
J Gen Virol 2010, 91:2687–2697.
23. Leifer I, Depner K, Blome S, Le Potier MF, Le Dimna M, Beer M, Hoffmann B:
Differentiation of C-strain "Riems" or CP7_E2alf vaccinated animals from
animals infected by classical swine fever virus field strains using
real-time RT-PCR. J Virol Methods 2009, 158:114–122.
24. Kaden V, Lange B: Oral immunisation against classical swine fever (CSF):
onset and duration of immunity. Vet Microbiol 2001, 82:301–310.
25. Reimann I, Depner K, Utke K, Leifer I, Lange E, Beer M: Characterization of a
new chimeric marker vaccine candidate with a mutated antigenic
E2-epitope. Vet Microbiol 2010, 142:45–50.
26. Hoffmann B, Beer M, Schelp C, Schirrmeier H, Depner K: Validation of a
real-time RT-PCR assay for sensitive and specific detection of classical
swine fever. J Virol Methods 2005, 130:36–44.
27. Holinka LG, Fernandez-Sainz I, O'Donnell V, Prarat MV, Gladue DP, Lu Z,
Risatti GR, Borca MV: Development of a live attenuated antigenic marker
classical swine fever vaccine. Virology 2005, 384:106–113.
28. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC: In vitro isolation of a
neutralization escape mutant of equine infectious anemia virus (EIAV).
Arch Virol 1990, 111:275–280.
doi:10.1186/1297-9716-43-33
Cite this article as: Leifer et al.: Characterization of C-strain “Riems”
TAV-epitope escape variants obtained through selective antibody
pressure in cell culture. Veterinary Research 2012 43:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
